Hereditary neuromuscular disorders are quite varied in their presentations and even more diverse in terms of their specific genetic causes. Sometimes, these disorders can be framed in terms of the extent of weakness, sensory involvement, and/or autonomic involvements, but in other instances, it may be difficult to discern the appropriate test for many patients based on phenotype.
At Mayo Clinic, we know the importance of laboratory testing in a patient’s episode of care. Our unique combination of specialized laboratories and neurology patient care clinics gives us the ability to put into practice clinically proven, cost-effective, patient care-driven testing approaches for hundreds of neurological conditions.
Mayo Medical Laboratories is the first clinical laboratory to offer postmortem genetic tests for inheritable cardiovascular disorders on formalin-fixed paraffin-embedded (FFPE) tissue as a preferred sample type.
Multiple myeloma is the second most common blood cancer, but most people haven’t heard of it until they or someone they know is diagnosed with the disease. March is Myeloma Action Month—a time to focus attention on the fight against multiple myeloma.
Mayo Clinic offers a different approach compared to traditional pain-management testing because our Pain Clinic Survey only tests for the most common drugs of abuse, primarily those characterized as Tier I in the American Association for Clinical Chemistry’s laboratory medicine practice guideline. Testing for less-common drugs is only recommended in high-risk patients or when clinically indicated, which leads to more appropriate test utilization, saving ordering institutions time and money.
With more than 70,000 uses worldwide and policy endorsements for its use (JAMA Article), the Mayo Clinic Statin Choice Decision-Aid tool is helping patients and their clinicians have meaningful conversations about whether or not to use statins to reduce cardiovascular risk.